Yestar Healthcare Holdings Company Limited (Stock Code: 2393) has disclosed two acquisitions aimed at expanding its capabilities in the advanced materials segment. An indirect wholly owned subsidiary of the company entered into two purchase agreements with a Hong Kong-based vendor to acquire production and testing equipment.

On 21 October 2025, the subsidiary purchased pre-crosslink mixing, coating, feeding, and evaluation systems, along with other accessories, for US$1,850,000. Payment for this equipment was arranged within three months after signing, with delivery expected within four months of payment.

On 6 February 2026, a second agreement was signed for additional production and testing equipment, including a membrane coating production line, evaluation and packaging systems, plasma treatment systems, as well as consumables and materials, at a consideration of US$5,350,000. Funding comes from internal resources, with similar payment and delivery terms.

Following both agreements, the company’s aggregated acquisitions meet the threshold for discloseable transactions under Hong Kong Listing Rules. According to the announcement, these purchases are part of the company’s plan to invest in advanced materials research and manufacturing, leveraging its existing production experience to diversify into new business segments.